Literature DB >> 30429363

NF-κB/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification.

Emilie Barruet1, Blanca M Morales1, Corey J Cain1, Amy N Ton1, Kelly L Wentworth1, Tea V Chan1, Tania A Moody1, Mariëlle C Haks2, Tom Hm Ottenhoff2, Judith Hellman3, Mary C Nakamura4, Edward C Hsiao1.   

Abstract

BACKGROUND: Inflammation helps regulate normal growth and tissue repair. Although bone morphogenetic proteins (BMPs) and inflammation are known contributors to abnormal bone formation, how these pathways interact in ossification remains unclear.
METHODS: We examined this potential link in patients with fibrodysplasia ossificans progressiva (FOP), a genetic condition of progressive heterotopic ossification caused by activating mutations in the Activin A type I receptor (ACVR1/ALK2). FOP patients show exquisite sensitivity to trauma, suggesting that BMP pathway activation may alter immune responses. We studied primary blood, monocyte, and macrophage samples from control and FOP subjects using multiplex cytokine, gene expression, and protein analyses; examined CD14+ primary monocyte and macrophage responses to TLR ligands; and assayed BMP, TGF-β activated kinase 1 (TAK1), and NF-κB pathways.
RESULTS: FOP subjects at baseline without clinically evident heterotopic ossification showed increased serum IL-3, IL-7, IL-8, and IL-10. CD14+ primary monocytes treated with the TLR4 activator LPS showed increased CCL5, CCR7, and CXCL10; abnormal cytokine/chemokine secretion; and prolonged activation of the NF-κB pathway. FOP macrophages derived from primary monocytes also showed abnormal cytokine/chemokine secretion, increased TGF-β production, and p38MAPK activation. Surprisingly, SMAD phosphorylation was not significantly changed in the FOP monocytes/macrophages.
CONCLUSIONS: Abnormal ACVR1 activity causes a proinflammatory state via increased NF-κB and p38MAPK activity. Similar changes may contribute to other types of heterotopic ossification, such as in scleroderma and dermatomyositis; after trauma; or with recombinant BMP-induced bone fusion. Our findings suggest that chronic antiinflammatory treatment may be useful for heterotopic ossification.

Entities:  

Keywords:  Bone Biology; Bone disease; Cellular immune response; Genetic diseases; Inflammation

Mesh:

Substances:

Year:  2018        PMID: 30429363      PMCID: PMC6302947          DOI: 10.1172/jci.insight.122958

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  108 in total

Review 1.  Fractalkine/CX3CL1: a potential new target for inflammatory diseases.

Authors:  Brian A Jones; Maria Beamer; Salahuddin Ahmed
Journal:  Mol Interv       Date:  2010-10

2.  Characterizing the genetic basis of innate immune response in TLR4-activated human monocytes.

Authors:  Sarah Kim; Jessica Becker; Matthias Bechheim; Vera Kaiser; Mahdad Noursadeghi; Nadine Fricker; Esther Beier; Sven Klaschik; Peter Boor; Timo Hess; Andrea Hofmann; Stefan Holdenrieder; Jens R Wendland; Holger Fröhlich; Gunther Hartmann; Markus M Nöthen; Bertram Müller-Myhsok; Benno Pütz; Veit Hornung; Johannes Schumacher
Journal:  Nat Commun       Date:  2014-10-20       Impact factor: 14.919

Review 3.  Immunoregulation by members of the TGFβ superfamily.

Authors:  WanJun Chen; Peter Ten Dijke
Journal:  Nat Rev Immunol       Date:  2016-11-25       Impact factor: 53.106

Review 4.  AP-1 as a regulator of cell life and death.

Authors:  Eitan Shaulian; Michael Karin
Journal:  Nat Cell Biol       Date:  2002-05       Impact factor: 28.824

5.  Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.

Authors:  Gin-Ah Song; Hyun-Jung Kim; Kyung-Mi Woo; Jeong-Hwa Baek; Gwan-Shik Kim; Jin-Young Choi; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2010-05-12       Impact factor: 5.157

6.  Heterotopic ossification following traumatic and combat-related amputations. Prevalence, risk factors, and preliminary results of excision.

Authors:  Benjamin K Potter; Travis C Burns; Anton P Lacap; Robert R Granville; Donald A Gajewski
Journal:  J Bone Joint Surg Am       Date:  2007-03       Impact factor: 5.284

7.  Clinical significance of the heterotopic ossification after total hip arthroplasty.

Authors:  Mirjana Kocic; Milica Lazovic; Milorad Mitkovic; Biljana Djokic
Journal:  Orthopedics       Date:  2010-01       Impact factor: 1.390

Review 8.  Macrophage cytokines: involvement in immunity and infectious diseases.

Authors:  Guillermo Arango Duque; Albert Descoteaux
Journal:  Front Immunol       Date:  2014-10-07       Impact factor: 7.561

9.  Evaluation of Salivary Cytokines for Diagnosis of both Trauma-Induced and Genetic Heterotopic Ossification.

Authors:  Hsiao Hsin Sung Hsieh; Michael T Chung; Ronald M Allen; Kavitha Ranganathan; Joe Habbouche; David Cholok; Jonathan Butts; Arminder Kaura; Ramkumar Tiruvannamalai-Annamalai; Chris Breuler; Caitlin Priest; Shawn J Loder; John Li; Shuli Li; Jan Stegemann; Steven L Kunkel; Benjamin Levi
Journal:  Front Endocrinol (Lausanne)       Date:  2017-04-24       Impact factor: 5.555

10.  Fractalkine preferentially mediates arrest and migration of CD16+ monocytes.

Authors:  Petronela Ancuta; Ravi Rao; Ashlee Moses; Andrew Mehle; Sunil K Shaw; F William Luscinskas; Dana Gabuzda
Journal:  J Exp Med       Date:  2003-06-16       Impact factor: 14.307

View more
  23 in total

Review 1.  Inflammation in Fibrodysplasia Ossificans Progressiva and Other Forms of Heterotopic Ossification.

Authors:  Koji Matsuo; Robert Dalton Chavez; Emilie Barruet; Edward C Hsiao
Journal:  Curr Osteoporos Rep       Date:  2019-12       Impact factor: 5.096

2.  Suppression of heterotopic ossification in fibrodysplasia ossificans progressiva using AAV gene delivery.

Authors:  Yeon-Suk Yang; Jung-Min Kim; Jun Xie; Sachin Chaugule; Chujiao Lin; Hong Ma; Edward Hsiao; Jaehyoung Hong; Hyonho Chun; Eileen M Shore; Frederick S Kaplan; Guangping Gao; Jae-Hyuck Shim
Journal:  Nat Commun       Date:  2022-10-19       Impact factor: 17.694

3.  An ACVR1 activating mutation causes neuropathic pain and sensory neuron hyperexcitability in humans.

Authors:  Xiaobing Yu; Amy N Ton; Zejun Niu; Blanca M Morales; Jiadong Chen; Joao Braz; Michael H Lai; Emilie Barruet; Hongju Liu; Kin Cheung; Syed Ali; Tea Chan; Katherine Bigay; Jennifer Ho; Ina Nikolli; Steven Hansberry; Kelly Wentworth; Arnold Kriegstein; Allan Basbaum; Edward C Hsiao
Journal:  Pain       Date:  2022-04-20       Impact factor: 7.926

Review 4.  Cardiopulmonary and Neurologic Dysfunctions in Fibrodysplasia Ossificans Progressiva.

Authors:  Fatima Khan; Xiaobing Yu; Edward C Hsiao
Journal:  Biomedicines       Date:  2021-02-05

5.  A Rare Mutation in SMAD9 Associated With High Bone Mass Identifies the SMAD-Dependent BMP Signaling Pathway as a Potential Anabolic Target for Osteoporosis.

Authors:  Celia L Gregson; Dylan J M Bergen; Paul Leo; Richard B Sessions; Lawrie Wheeler; April Hartley; Scott Youlten; Peter I Croucher; Aideen M McInerney-Leo; William Fraser; Jonathan Cy Tang; Lisa Anderson; Mhairi Marshall; Leon Sergot; Lavinia Paternoster; George Davey Smith; Matthew A Brown; Chrissy Hammond; John P Kemp; Jon H Tobias; Emma L Duncan
Journal:  J Bone Miner Res       Date:  2019-11-14       Impact factor: 6.390

6.  ACVR1R206H extends inflammatory responses in human induced pluripotent stem cell-derived macrophages.

Authors:  Koji Matsuo; Abigail Lepinski; Robert D Chavez; Emilie Barruet; Ashley Pereira; Tania A Moody; Amy N Ton; Aditi Sharma; Judith Hellman; Kiichiro Tomoda; Mary C Nakamura; Edward C Hsiao
Journal:  Bone       Date:  2021-07-24       Impact factor: 4.398

7.  Targeting local lymphatics to ameliorate heterotopic ossification via FGFR3-BMPR1a pathway.

Authors:  Dali Zhang; Junlan Huang; Xianding Sun; Hangang Chen; Shuo Huang; Jing Yang; Xiaolan Du; Qiaoyan Tan; Fengtao Luo; Ruobin Zhang; Siru Zhou; Wanling Jiang; Zhenhong Ni; Zuqiang Wang; Min Jin; Meng Xu; Fangfang Li; Liang Chen; Mi Liu; Nan Su; Xiaoqing Luo; Liangjun Yin; Ying Zhu; Jerry Q Feng; Di Chen; Huabing Qi; Lin Chen; Yangli Xie
Journal:  Nat Commun       Date:  2021-07-19       Impact factor: 14.919

8.  Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome?

Authors:  Ruby Haviv; Veronica Moshe; Fabrizio De Benedetti; Giusi Prencipe; Noa Rabinowicz; Yosef Uziel
Journal:  Pediatr Rheumatol Online J       Date:  2019-12-21       Impact factor: 3.054

9.  Silencing of SPARC represses heterotopic ossification via inhibition of the MAPK signaling pathway.

Authors:  Qianjun Wang; Qianqian Yang; Ali Zhang; Zhiqiang Kang; Yingsheng Wang; Zhentao Zhang
Journal:  Biosci Rep       Date:  2019-11-29       Impact factor: 3.840

Review 10.  Fibrodysplasia ossificans progressiva: current concepts from bench to bedside.

Authors:  Arun-Kumar Kaliya-Perumal; Tom J Carney; Philip W Ingham
Journal:  Dis Model Mech       Date:  2020-09-21       Impact factor: 5.758

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.